Safety and pharmacokinetics: colloidal bismuth subcitrate.

Safety and pharmacokinetics: colloidal bismuth subcitrate. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Safety and pharmacokinetics: colloidal bismuth subcitrate. Abstract Text:

L Z Benet,

Recent studies on oral administration of colloidal bismuth subcitrate suggest that, on average, the blood clearance of bismuth ranges from 50 to 95 ml/min, whereas the bioavailability of bismuth ranges from 0.16 to 0.28%. The higher values in each case assume that biliary clearance is a significant portion of the elimination, whereas the lower values assume only renal clearance. A minimal three-compartment model is necessary to describe the blood and urine excretion time-course data of bismuth. However, the intermediate half-life of 5-11 days represents most of the clearance and elimination. The Hillemand proposal that steady-state blood concentrations of greater than 50 ng/ml and greater than 100 ng/ml should be used as safety and alarm levels, respectively, for bismuth toxicity are probably overcautious, with little expectation of bismuth neurotoxicity associated with steady-state concentrations of 50-100 ng/ml. There is no clinical evidence to suggest that the transient high peak concentrations observed after oral doses of certain bismuth preparations are in any way related to toxicity. Pharmacokinetic theory suggests that initial high peak concentrations would result in only negligible increases in the predicted steady-state blood concentrations and steady-state amounts of drug in the body.

Safety and pharmacokinetics: colloidal bismuth subcitrate. Publishing Authors By Initials

LZ Benet,

For similar organic chemicals: organometallic compounds research abstracts see: organic chemicals: organometallic compounds research

PUBMED ID PMID:

MEDLINE DATE:

Safety and pharmacokinetics: colloidal bismuth subcitrate. Journal Published:

PUBLICATION TYPE: Review

Journal: Scandinavian journal of gastroenterology. Suppleme

VOLUME: 185

Page Numbers: 29-35

Journal Abbreviation: Scand. J. Gastroenterol. Suppl

ISSN: 0085-5928

DAY: 13

MONTH: 02

YEAR: 1991

Safety and pharmacokinetics: colloidal bismuth subcitrate. Information

Number of References: 25

LANGUAGE: eng

NlmUniqueID: 437034

Safety and pharmacokinetics: colloidal bismuth subcitrate. Keywords Mesh Terms:

KEYWORDS: Organometallic Compounds

MESH TERMS: pharmacokinetics

Chemical & Substance for Abstract: Safety and pharmacokinetics: colloidal bismuth subcitrate. Information

Substance Name: bismuth tripotassium dicitrate

Registry Number: 57644-54-9

Grant and Affiliation Information for Safety and pharmacokinetics: colloidal bismuth subcitrate.

AFFILIATION: Dept. of Pharmacy, University of California, San Francisco 94143-0446.

Country: NORWAY

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Scand J Gastroenterol Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Safety and pharmacokinetics: colloidal bismuth subcitrate Related Publications

• Biochemical mechanisms of cyclosporine neurotoxicity.
• Differential effects of fibrates on the metabolic activation of 2-phenylpropionic acid in rats.
• Effects of uptake and efflux transporter inhibition on erythromycin breath test results.
• Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism.
• Immunosuppressant Pharmacokinetics and Dosing Modifications in HIV-1 Infected Liver and Kidney Transplant Recipients.
• Pharmacokinetic parameters: which are necessary to define a drug substance?
• Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption.
• Safety and pharmacokinetics: colloidal bismuth subcitrate.
• effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.